[{"id":"ad90e007-a3c1-49d9-b0e8-6b7dc8b99352","acronym":"SGR-2921-101","url":"https://clinicaltrials.gov/study/NCT05961839","created_at":"2023-07-27T18:09:12.809Z","updated_at":"2024-07-02T16:35:07.384Z","phase":"Phase 1","brief_title":"Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05961839 - SGR-2921-101","lead_sponsor":"Schrödinger, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SGR-2921"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-26"},{"id":"92e4c7fb-dc6e-4dd1-b4cc-48967c24d056","acronym":"CRUKD/17/004","url":"https://clinicaltrials.gov/study/NCT03096054","created_at":"2021-01-18T15:15:19.278Z","updated_at":"2024-07-02T16:35:32.984Z","phase":"Phase 1","brief_title":"A CR-UK Phase I Trial of LY3143921","source_id_and_acronym":"NCT03096054 - CRUKD/17/004","lead_sponsor":"Cancer Research UK","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3143921"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2023-10-18"},{"id":"fa5846d1-0a7a-44da-91ce-c0f902f44674","acronym":"","url":"https://clinicaltrials.gov/study/NCT03708211","created_at":"2021-01-18T18:10:52.137Z","updated_at":"2024-07-02T16:36:36.774Z","phase":"Phase 1","brief_title":"A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03708211","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simurosertib (TAK-931)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 12/03/2019","primary_completion_date":" 12/03/2019","study_txt":" Completion: 12/03/2019","study_completion_date":" 12/03/2019","last_update_posted":"2020-12-29"}]